Multiple system atrophy and apolipoprotein E
- PMID: 29442376
- PMCID: PMC5889322
- DOI: 10.1002/mds.27297
Multiple system atrophy and apolipoprotein E
Abstract
Background: Dysregulation of the specialized lipid metabolism involved in myelin synthesis and maintenance by oligodendrocytes has been associated with the unique neuropathology of MSA. We hypothesized that apolipoprotein E, which is associated with neurodegeneration, may also play a role in the pathogenesis of MSA.
Objective: This study evaluated genetic associations of Apolipoprotein E alleles with risk of MSA and α-synuclein pathology, and also examined whether apolipoprotein E isoforms differentially affect α-synuclein uptake in a oligodendrocyte cell.
Methods: One hundred sixty-eight pathologically confirmed MSA patients, 89 clinically diagnosed MSA patients, and 1,277 control subjects were genotyped for Apolipoprotein E. Human oligodendrocyte cell lines were incubated with α-synuclein and recombinant human apolipoprotein E, with internalized α-synuclein imaged by confocal microscopy and cells analyzed by flow cytometry.
Results: No significant association with risk of MSA or was observed for either Apolipoprotein E ɛ2 or ɛ4. α-Synuclein burden was also not associated with Apolipoprotein E alleles in the pathologically confirmed patients. Interestingly, in our cell assays, apolipoprotein E ɛ4 significantly reduced α-synuclein uptake in the oligodendrocytic cell line.
Conclusions: Despite differential effects of apolipoprotein E isoforms on α-synuclein uptake in a human oligodendrocytic cell, we did not observe a significant association at the Apolipoprotein E locus with risk of MSA or α-synuclein pathology. © 2018 International Parkinson and Movement Disorder Society.
Keywords: apolipoprotein E; genetics; multiple system atrophy; oligodendrocyte; protection.
© 2018 International Parkinson and Movement Disorder Society.
Figures

References
-
- Trojanowski JQ, Revesz T Neuropathology Working Group on MSA. Proposed neuropathological criteria for the post mortem diagnosis of multiple system atrophy. Neuropathol Appl Neurobiol. 2007;33(6):615–620. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 FD004789/FD/FDA HHS/United States
- R01 NS078086/NS/NINDS NIH HHS/United States
- R01 AG046205/AG/NIA NIH HHS/United States
- P50 AG016574/AG/NIA NIH HHS/United States
- R01 NS092625/NS/NINDS NIH HHS/United States
- K23 NS075141/NS/NINDS NIH HHS/United States
- RF1 AG051504/AG/NIA NIH HHS/United States
- R01 AG027924/AG/NIA NIH HHS/United States
- P50 NS072187/NS/NINDS NIH HHS/United States
- RF1 AG046205/AG/NIA NIH HHS/United States
- P01 NS044233/NS/NINDS NIH HHS/United States
- R01 AG035355/AG/NIA NIH HHS/United States
- R01 NS057567/NS/NINDS NIH HHS/United States
- U54 NS065736/NS/NINDS NIH HHS/United States
- P01 NS074969/NS/NINDS NIH HHS/United States
- P01 AG003949/AG/NIA NIH HHS/United States
- UL1 RR024150/RR/NCRR NIH HHS/United States
- U01 AG006786/AG/NIA NIH HHS/United States
- U54 NS100693/NS/NINDS NIH HHS/United States